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The Vascular Smooth Muscle Cells Apoptosis in Asymptomatic Diabetic Carotid Plaques:
Role of Glycemic Control
To the Editor: Atherosclerotic plaque instability is enhanced in
diabetes, and it determines the increased incidence and severity
of clinical events (1). A variety of proinflammatory cytokines,
including tumor necrosis factor (TNF)-9 and interleukin (IL)-
1, alone or in conjunction have the potential to promote
plaque instability, inducing apoptosis (2). Vascular smooth
muscle cell (VSMC) apoptosis has been identified in advanced
human atherosclerotic plaques and is increased in unstable
versus stable lesions (3). Although it has been demonstrated
that diabetes mellitus may enhance apoptosis in myocardial (4)
and endothelial cells (5), still, no evidence exists in humans
about the potential role of diabetes in the evolution of diabetic
atherosclerotic plaques toward instability by enhancing VSMC
apoptosis. We hypothesize that by enhancing the proinflamma-
tory cytokines, diabetes may exert proapoptotic effects on
VSMCs of atherosclerotic plaque. To address these issues, cell
death by apoptosis and expression and localization of TNF-9
and IL-1 was evaluated in carotid plaques of asymptomatic
diabetic and nondiabetic patients.
The study group consisted of 26 type 2 diabetic and 30
nondiabetic patients enlisted to undergo carotid endarterectomy
for asymptomatic extracranial high-grade (70%) internal carotid
artery stenosis (6). Written informed consent was obtained from all
patients. The local ethics review committee approved the study.
After surgery, the specimens were cut perpendicular to the long
axis into two halves. The first half was frozen in liquid nitrogen,
lysed, and centrifuged for the following enzyme-linked immu-
nosorbent assay analysis. Caspase-3, TNF-, IL-1 and nitroty-
rosine levels were quantified in plaques using specific kits (R&D
Systems, Minneapolis, Minnesota; Imgenex, Oxford, United
Kingdom). A portion of the other half specimen was immedi-
ately immersion-fixed in 10% buffered formalin. Serial sections
were incubated with specific antibodies -smooth muscle (SM)
actin and anti-CD68; anti–TNF-, IL-1 and active caspase-3
as well as terminal deoxynucleotidyl transferase end-labeling
(TUNEL).
Clinical data for the study population are presented in Table
1. In nondiabetic subjects, the presence of type 2 diabetes
mellitus or impaired glucose tolerance was tested by oral glucose
tolerance test. Compared with nondiabetic patients, diabetic
patients had significantly greater portion of plaque area occu-
pied by macrophages (24.5  5% vs. 5  2% of the total area;
p  0.01) (Fig. 1) and lower content of interstitial collagen (p
 0.01) (Fig. 1). The nondiabetic plaques were composed
primarily of longitudinally oriented SMCs that strongly ex-
pressed -SMC actin (18  6% of the total area). However,
-SMC immunoreactivity was much lower in the diabetic
plaques (9  7% of the total area) (Fig. 1). We detected IL-1
and TNF- in 22 of 26 diabetic plaques, whereas the same
cytokines were detected in only 12 of 30 nondiabetic plaques.
Compared with nondiabetic lesions, diabetic plaques had higher
levels of IL-1 and TNF- (p  0.01) (Fig. 1). Notably, IL-1
and TNF- plaque levels were strongly dependent on glycemic
control, as also reflected by the statistically significant correla-
tion between plasma HbA1c and cytokine plaque levels (IL-1:
r  0.49, p  0.001; TNF-: r  0.51, p  0.001). The
TUNEL labeling disclosed evidence of apoptosis in 32 (57%) of
Table 1. Characteristics of Study Patients
Variables
Diabetic
Patients
(n  26)
Nondiabetic
Patients
(n  30)
Age (yrs) 68  3 69  2
Men/women 15/11 16/14
Patient characteristics
Family history of IHD 15 14
Hypertension 11 15
Hypercholesterolemia 10 13
Cigarette smoking 7 12
Coronary artery disease 14 13
BMI (kg/m2) 28.2  2 27.6  2
Systolic blood pressure (mm Hg) 129  11 128  12
Diastolic blood pressure (mm Hg) 81  4 81  4
HbA1c (%) 8.1  1.4 4.9  1.1*
Fasting blood glucose (mmol/l) 9.7  1.4 6  0.9*
Insulin (U/ml) 10.6  2.4 8.06  3.3*
Total cholesterol (mmol/l) 5.53  0.03 5.39  0.06
HDL cholesterol (mmol/l) 1.22  0.03 1.29  0.04
Triglycerides (mmol/l) 2.31  0.11 2.21  0.12
Stenosis severity (%) 76.4  4.5 75.5  4.9
Percentage of macrophage-rich areas 24  5 5  2*
No. of T cells per mm2 section area 70  13 15  7*
Percentage of expression of HLA-DR 21  6 13  7*
Percentage of VSMC-rich areas 9  7 18  6
Active therapy
Aspirin 21 24
Warfarin 1 2
Beta-blocker 5 7
Calcium channel blocker 4 3
Statin 17 20
ACE inhibitor 14 16
Diuretic agent 6 9
AT-2 antagonist 12 14
Insulin 5 —
Sulfonylureas 20 —
Thiazolidinediones 1 —
Metformin 14 —
Data are presented as n or mean SD. HbA1c normal values: 4% to 6.2%. *p 0.05
compared with diabetic group. Continuous variables were compared among the
groups of patients with an independent Student t test for normally distributed data
and Wilcoxon test for non-normally distributed data. The Kolmogorov-Smirnov test
was used to assess whether continuous variables were normally distributed. We
compared data using a Wilcoxon test for nitrotyrosine, interleukin-1, tumor necrosis
factor-, triglycerides, and insulin. Differences between measured variables were
considered significant if the resultant p value was 0.05 or less. The strength of the
association of plasma HbA1c with caspase-3 and cytokine levels in plaque specimens
was assessed by linear regression analysis. The influence of HbA1c on plaque features
was evaluated using multivariate analysis. All calculations were performed using the
computer program SPSS 12.
ACE  angiotensin-converting enzyme; BMI  body mass index; HDL 
high-density lipoprotein; IHD  ischemic heart disease; VSMC  vascular smooth
muscle cell.
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the total 56 specimens studied. Among 26 diabetic plaques, 24
(92%) contained foci of apoptosis; in contrast, apoptosis was
observed in only 8 (27%) of 30 nondiabetic plaques (p  0.01).
Among nondiabetic plaques, apoptosis was typically limited
to 2% of cells. Among diabetic plaques, the frequency of
apoptotic cells ranged from 0.10% to 18% (4.9  6.5%).
Compared with nondiabetic plaques, diabetic plaques revealed
higher levels of caspase-3 (p  0.01) (Fig. 1). Notably,
caspase-3 levels in plaque specimens were strongly dependent
on glycemic control (r  0.533, p  0.001). Diabetic plaques
had significantly higher percentage of TUNEL-positive
VSMCs compared with nondiabetic plaques (p  0.01) (Fig. 1).
Higher nitrotyrosine levels were found in diabetic as compared
with nondiabetic plaques (p  0.001) (Fig. 1). Most TUNEL-
positive diabetic plaques (75%) showed higher levels of TNF-
and nitrotyrosine levels. Conversely, most fields that were not
Figure 1. Percentage of interstitial collagen (Sirius red staining for collagen content), macrophage-rich areas, -smooth muscle cell (SMC) actin and
terminal deoxynucleotidyl transferase end-labeling (TUNEL)-positive vascular smooth muscle cells (VSMCs) in diabetic and nondiabetic plaques (to
identify vascular smooth muscle cells undergoing apoptosis, double staining was performed with TUNEL and periodic acid-Schiff staining or TUNEL and
-smooth muscle actin staining). The bars show levels of nitrotyrosine, active caspase-3, interleukin-1, and tumor necrosis factor- in diabetic and
nondiabetic plaques (The central line represents the median, the boxes span from the 25th to 75th percentiles, and the error bars extend from the 10th
to 90th percentiles). *p  0.05 compared with nondiabetic patients.
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TUNEL-positive (72%) showed moderate to low levels of
TNF- and nitrotyrosine levels. Moreover, by multivariate
analysis, HbA1c was independently related to VSMC apopto-
sis, as showed by TUNEL-positive VSMCs and caspase-3
levels (p  0.030 and p  0.026, respectively).
Our study shows that VSMC apoptosis may be involved in
the evolution of diabetic plaques toward instability. In partic-
ular, VSMC apoptosis is greater in diabetic lesions than
nondiabetic lesions and was associated with higher TNF- and
IL-1 levels along with lower interstitial collagen and -SMC
actin content. All this would make diabetic plaques more prone
to inflammatory-dependent rupture and might increase the risk
of cerebrovascular ischemic events (7,8). In our study, macro-
phages were more abundant in diabetic plaques and represented the
major source of inflammatory cytokines, suggesting the presence of an
active inflammatory reaction in diabetic plaques. In agreement with
the difference in apoptosis staining pattern, the histologic milieu of
the lesions appears different with regard to cellularity, but not in
the degree of vessel stenosis, suggesting that diabetic and nondi-
abetic lesions are different only with regard to inflammatory
burden. Hence, the differences in plaque behavior likely stem from
differences in the presence of stimuli (i.e., persistent hyperglycemia
and oxidative stress, as evidenced by high HbA1c and nitrotyrosine
levels) for selective expression of TNF- or IL-1 capable of
disrupting plaque stability via VSMC apoptosis. Notably, the intrigu-
ing and novel proatherogenic mechanism of apoptosis in human
diabetes is supported in this study not only by the observation that
VSMC apoptosis is higher in diabetic plaques, but also by the
information that it is strongly correlated with the intensity of
glycemic control as reflected by HbA1c. The mechanism of the
relationship of cytokines with the VSMC apoptotic process re-
mains uncertain in diabetic plaques. However, TNF- and IL-1
do not act in isolation, as macrophage-induced VSMC apoptosis
through formation of peroxynitrite also requires nitric oxide and
oxygen free radicals (9). This suggests that cooperative interactions
might occur between these mediators, and the present study
outlines such associations demonstrating a presence of overpro-
duction of nitrotyrosine, a good marker of peroxynitrite formation
(10), in diabetic plaques that was not present in nondiabetic
lesions. Indeed, these stimuli of diabetic milieu can also induce
apoptosis of endothelial cells, resulting in vascular leak and
inflammation, which are implicated in the pathogenesis of vascular
diseases (3). This study demonstrates enhanced VSMC apoptosis
in diabetic carotid atherosclerotic lesions and provides evidence
that the activation of this mechanism by inflammatory cells is
associated with an increase in oxidative stress potentially promoting
plaque rupture. These findings are potentially important from a
fundamental standpoint, because they indicate a pathogenetic role for
the VSMC apoptosis in the evolution of diabetic atherosclerotic
lesions. From a practical standpoint, these findings provide further
support for the role of glycemic control on plaque stabilization in
diabetic patients with atherosclerotic disease.
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Evidence of Cocaine-Related Coronary Atherosclerosis in Young Patients
With Myocardial Infarction
To the Editor: Cocaine use has increased in the last years reaching
in 1999 in the U.S. 30% of all drug-related visits to the emergency
department, exceeding morphine and representing the most fre-
quent cause of drug-related deaths (1). One of every four myocar-
dial infarctions (MIs) in people aged 18 to 45 years can be linked
to cocaine use (2). Several reports (3) implicated coronary vaso-
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